Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Early study backs Pharmacyclics' MRI (magnetic resonance imaging) agent:

This article was originally published in Clinica

Executive Summary

Pharmacyclics has presented additional data supporting the use of its texaphyrin MRI-based agent for detecting vulnerable atherosclerotic plaque. Preclinical data, presented at this month's Society for Cardiac Magnetic Resonance in San Francisco, showed the gadolinium-based texaphyrin compound localised in plaque and enhanced MRI signal in atherosclerotic animal models. The Sunnyvale, California firm is currently developing Antrin, a texaphyrin-based, light-activated product for treating peripheral arterial disease and coronary artery disease.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts